DGIdb - GNAQ Gene Record

GNAQ 2776 Clinically ActionableDrug Resistance

Alternate Names:

2776
G PROTEIN SUBUNIT ALPHA Q
GNAQ
CMC1
G-ALPHA-q
GAQ
SWS
600998
4390
ENSG00000156052
OTTHUMG00000020059
2317

Gene Info:

Gene Biotype	PROTEIN_CODING

(5 More Sources)

Gene Categories: Category Details

DRUG RESISTANCE
CLINICALLY ACTIONABLE

Publications:

Lyubasyuk et al., YAP inhibition blocks uveal melanogenesis driven by GNAQ or GNA11 mutations., Mol Cell Oncol
Carita et al., 2016, Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma., Oncotarget
Ambrosini et al., 2012, Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance., Clin. Cancer Res.
Khalili et al., 2012, Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner., Clin. Cancer Res.
Wu et al., 2012, The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma., PLoS ONE
Landis et al., 1989, GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours., Nature
Ho et al., 2012, Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype., PLoS ONE
Wu et al., 2012, Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways., Mol. Cancer Ther.
Van Raamsdonk et al., 2010, Mutations in GNA11 in uveal melanoma., N. Engl. J. Med.
Van Raamsdonk et al., 2009, Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi., Nature
Onken et al., 2008, Oncogenic mutations in GNAQ occur early in uveal melanoma., Invest. Ophthalmol. Vis. Sci.
Kalinec et al., 1992, Mutated alpha subunit of the Gq protein induces malignant transformation in NIH 3T3 cells., Mol. Cell. Biol.
MacConaill et al., 2014, Prospective enterprise-level molecular genotyping of a cohort of cancer patients., J Mol Diagn
Weekes et al., 2013, Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer., Clin. Cancer Res.
Turajlic et al., 2014, Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition., Ann. Oncol.
Chen et al., 2014, Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations., Oncogene
von Euw et al., 2012, Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines., Mol. Cancer

VERTEPORFIN GNAQ

Interaction Score: 4.76

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type uveal melanoma

Response Type sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
27308390

Sources:
JAX-CKB
SELUMETINIB GNAQ

Interaction Score: 1.77

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell culture

Response Type sensitive

PMIDs:
22550165 22733540 22253748 2549426 22808163 22653968 21083380 19078957 18719078 1328859 25157968

Sources:
JAX-CKB DoCM
CGM-097 GNAQ

Interaction Score: 1.59

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AEB071 + CGM097

Indication/Tumor Type uveal melanoma

Response Type predicted – sensitive

PMIDs:
27507190

Sources:
JAX-CKB
REFAMETINIB GNAQ

Interaction Score: 1.36

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type ocular melanoma

Response Type predicted – sensitive

Approval Status Phase I

PMIDs:
23434733

Sources:
JAX-CKB
TAK-733 GNAQ

Interaction Score: 1.19

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type uveal melanoma

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
22515704

Sources:
JAX-CKB
ENZASTAURIN GNAQ

Interaction Score: 1.19

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type uveal melanoma

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
22253748

Sources:
JAX-CKB
PLX-4720 GNAQ

Interaction Score: 1.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24504448

Sources:
CIViC
PD-0325901 GNAQ

Interaction Score: 0.86

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AEB071 + PD-0325901

Indication/Tumor Type uveal melanoma

Response Type sensitive

PMIDs:
24141786

Sources:
JAX-CKB
BINIMETINIB GNAQ

Interaction Score: 0.53

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy MEK162 + AEB071

Indication/Tumor Type uveal melanoma

Response Type predicted – sensitive

PMIDs:
27507190

Sources:
JAX-CKB
OMIPALISIB GNAQ

Interaction Score: 0.5

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy GSK2126458 + Trametinib

Indication/Tumor Type uveal melanoma

Response Type sensitive

PMIDs:
22733540

Sources:
JAX-CKB
SOTRASTAURIN GNAQ

Interaction Score: 0.33

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AEB071 + CGM097

Indication/Tumor Type uveal melanoma

Response Type predicted – sensitive

PMIDs:
22653968 24141786 27507190

Sources:
JAX-CKB
EVEROLIMUS GNAQ

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AEB071 + Everolimus

Indication/Tumor Type uveal melanoma

Response Type predicted – sensitive

PMIDs:
27507190

Sources:
JAX-CKB
TRAMETINIB GNAQ

Interaction Score: 0.23

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy GSK2126458 + Trametinib

Indication/Tumor Type uveal melanoma

Response Type sensitive

PMIDs:
22733540

Sources:
JAX-CKB

Ensembl: ENSG00000156052
- Version: 101_38
Alternate Names:

GNAQ Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:

JAX-CKB: GNAQ

Version: 27-September-2017

Alternate Names:

2776 CKB Entrez Id

GNAQ CKB Gene Synonym

CMC1 CKB Gene Synonym

Gene Info:

Publications:

Lyubasyuk et al., YAP inhibition blocks uveal melanogenesis driven by GNAQ or GNA11 mutations., Mol Cell Oncol

Ambrosini et al., 2012, Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance., Clin. Cancer Res.

von Euw et al., 2012, Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines., Mol. Cancer

CIViC: GNAQ

Version: 14-September-2020

Alternate Names:

2776 Entrez Gene ID

2317 CIViC Gene ID

Gene Info:

Gene Categories:

DRUG RESISTANCE

Publications:

Chen et al., 2014, Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations., Oncogene

Turajlic et al., 2014, Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition., Ann. Oncol.

DoCM: GNAQ

Version: 27-September-2017

Alternate Names:

Gene Info:

Publications:

Landis et al., 1989, GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours., Nature

Wu et al., 2012, Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways., Mol. Cancer Ther.

Ho et al., 2012, Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype., PLoS ONE

Tempus: GNAQ
- Version: 11-November-2018
Alternate Names:

GNAQ Gene Symbol

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
MskImpact: GNAQ
- Version: May-2015
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
FoundationOneGenes: GNAQ
- Version: 03-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
CarisMolecularIntelligence: GNAQ
- Version: 04-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
Oncomine: GNAQ
- Version: v3
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:

Indication/Tumor Type	uveal melanoma
Response Type	sensitive
Approval Status	Preclinical - Cell line xenograft

Evidence Type	Actionable
Approval Status	Preclinical - Cell culture
Response Type	sensitive

combination therapy	AEB071 + CGM097
Indication/Tumor Type	uveal melanoma
Response Type	predicted – sensitive

Indication/Tumor Type	ocular melanoma
Response Type	predicted – sensitive
Approval Status	Phase I

combination therapy	AEB071 + PD-0325901
Indication/Tumor Type	uveal melanoma
Response Type	sensitive

combination therapy	MEK162 + AEB071
Indication/Tumor Type	uveal melanoma
Response Type	predicted – sensitive

combination therapy	GSK2126458 + Trametinib
Indication/Tumor Type	uveal melanoma
Response Type	sensitive

combination therapy	AEB071 + Everolimus
Indication/Tumor Type	uveal melanoma
Response Type	predicted – sensitive

GNAQ Gene Record

GNAQ 2776 Clinically ActionableDrug Resistance

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type uveal melanoma Response Type sensitive Approval Status Preclinical - Cell line xenograft

PMIDs: 27308390

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Evidence Type Actionable Approval Status Preclinical - Cell culture Response Type sensitive

PMIDs: 22550165 22733540 22253748 2549426 22808163 22653968 21083380 19078957 18719078 1328859 25157968

Sources: JAX-CKB DoCM

Interaction Types & Directionality: n/a

Interaction Info: combination therapy AEB071 + CGM097 Indication/Tumor Type uveal melanoma Response Type predicted – sensitive

PMIDs: 27507190

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type ocular melanoma Response Type predicted – sensitive Approval Status Phase I

PMIDs: 23434733

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type uveal melanoma Response Type sensitive Approval Status Preclinical - Cell culture

PMIDs: 22515704

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type uveal melanoma Response Type sensitive Approval Status Preclinical - Cell culture

PMIDs: 22253748

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24504448

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info: combination therapy AEB071 + PD-0325901 Indication/Tumor Type uveal melanoma Response Type sensitive

PMIDs: 24141786

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy MEK162 + AEB071 Indication/Tumor Type uveal melanoma Response Type predicted – sensitive

PMIDs: 27507190

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy GSK2126458 + Trametinib Indication/Tumor Type uveal melanoma Response Type sensitive

PMIDs: 22733540

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy AEB071 + CGM097 Indication/Tumor Type uveal melanoma Response Type predicted – sensitive

PMIDs: 22653968 24141786 27507190

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy AEB071 + Everolimus Indication/Tumor Type uveal melanoma Response Type predicted – sensitive

PMIDs: 27507190

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy GSK2126458 + Trametinib Indication/Tumor Type uveal melanoma Response Type sensitive

PMIDs: 22733540

Sources: JAX-CKB

Ensembl: ENSG00000156052

Alternate Names: GNAQ Ensembl Gene Name

Gene Info: Gene Biotype PROTEIN_CODING

Publications:

JAX-CKB: GNAQ

Alternate Names: 2776 CKB Entrez Id GNAQ CKB Gene Synonym CMC1 CKB Gene Synonym

Gene Info:

CIViC: GNAQ

Alternate Names: 2776 Entrez Gene ID 2317 CIViC Gene ID

Gene Info:

Gene Categories: DRUG RESISTANCE

Publications: Chen et al., 2014, Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations., Oncogene Turajlic et al., 2014, Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition., Ann. Oncol.

DoCM: GNAQ

Alternate Names:

Gene Info:

Tempus: GNAQ

Alternate Names: GNAQ Gene Symbol

Gene Info:

Gene Categories: CLINICALLY ACTIONABLE

Publications:

MskImpact: GNAQ

Alternate Names:

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type uveal melanoma

Response Type sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
27308390

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell culture

Response Type sensitive

PMIDs:
22550165 22733540 22253748 2549426 22808163 22653968 21083380 19078957 18719078 1328859 25157968

Sources:
JAX-CKB DoCM

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AEB071 + CGM097

Indication/Tumor Type uveal melanoma

Response Type predicted – sensitive

PMIDs:
27507190

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type ocular melanoma

Response Type predicted – sensitive

Approval Status Phase I

PMIDs:
23434733

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type uveal melanoma

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
22515704

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type uveal melanoma

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
22253748

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
24504448

Sources:
CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AEB071 + PD-0325901

Indication/Tumor Type uveal melanoma

Response Type sensitive

PMIDs:
24141786

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy MEK162 + AEB071

Indication/Tumor Type uveal melanoma

Response Type predicted – sensitive

PMIDs:
27507190

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy GSK2126458 + Trametinib

Indication/Tumor Type uveal melanoma

Response Type sensitive

PMIDs:
22733540

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AEB071 + CGM097

Indication/Tumor Type uveal melanoma

Response Type predicted – sensitive

PMIDs:
22653968 24141786 27507190

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AEB071 + Everolimus

Indication/Tumor Type uveal melanoma

Response Type predicted – sensitive

PMIDs:
27507190

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy GSK2126458 + Trametinib

Indication/Tumor Type uveal melanoma

Response Type sensitive

PMIDs:
22733540

Sources:
JAX-CKB

Alternate Names:

GNAQ Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Alternate Names:

2776 CKB Entrez Id

GNAQ CKB Gene Synonym

CMC1 CKB Gene Synonym

Alternate Names:

2776 Entrez Gene ID

2317 CIViC Gene ID

Gene Categories:

DRUG RESISTANCE

Publications:

Chen et al., 2014, Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations., Oncogene

Turajlic et al., 2014, Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition., Ann. Oncol.

Alternate Names:

GNAQ Gene Symbol

Gene Categories:

CLINICALLY ACTIONABLE

Gene Categories:

CLINICALLY ACTIONABLE

Gene Categories:

CLINICALLY ACTIONABLE

Gene Categories:

CLINICALLY ACTIONABLE

Gene Categories:

CLINICALLY ACTIONABLE